logo
President Biden's metastatic prostate cancer diagnosis: What you need to know

President Biden's metastatic prostate cancer diagnosis: What you need to know

CNN19-05-2025
EDITOR'S NOTE: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida's College of Medicine.
President Joe Biden's diagnosis of metastatic prostate cancer has understandably raised concerns and questions: How long has he had cancer, how will he be treated, and what is his prognosis?
As a urologist, I regularly diagnose prostate cancer in my patients, and each time I share the diagnosis with them and their family, it's never easy. Over time, I've learned the importance of keeping conversations simple and straightforward — avoiding sugar-coating and instead using data, statistics and personal experience to help patients begin their cancer journey.
As his public announcement draws attention to this type of cancer, it's a reminder to regularly check on your own health. Here's what you need to know about metastatic prostate cancer: how it's detected, what treatments look like, and why early screening remains essential for men's health.
The former president's diagnosis began after he experienced 'increasing urinary symptoms,' his office said, and a prostate nodule was discovered.
The detection of a prostate nodule likely happened during a digital rectal examination (DRE). During a DRE, a doctor gently inserts a finger into the rectum to examine the prostate gland, located directly in front of the rectal wall. A healthy prostate typically feels smooth and symmetrical. A prostate nodule, however, feels firm, raised, and irregular — similar in texture to your knuckles.
Not all prostate nodules indicate cancer — many are benign and associated with conditions enlarged prostate (BPH), or prostate stones (calcifications). However, in Biden's case, further testing — likely including a prostate-specific antigen (PSA) blood test, imaging and biopsy — confirmed prostate cancer. Additional scans revealed that his cancer had spread to his bones, classifying it as high-risk, aggressive metastatic prostate cancer.
'Metastatic' means the cancer cells have spread beyond the original location (the prostate gland) into other areas — most commonly bones and lymph nodes. Biden's cancer has specifically spread to his bones, placing him among the 5% to 7% of prostate cancer cases in the United States that are metastatic at initial diagnosis. While this percentage seems small, it represents a significant number given that over 300,000 men in the US and approximately 1.5 million worldwide are diagnosed with prostate cancer every year.
Early-stage prostate cancer carries an excellent prognosis, with nearly a 100% five-year survival rate. However, when prostate cancer is metastatic at diagnosis, the five-year survival rate drops sharply to around 37%. Importantly, these survival rates are statistical averages, and individual outcomes vary considerably based on overall health, age, cancer aggressiveness, and how well a patient responds to treatment.
For Biden — and all prostate cancer patients — this diagnosis marks the beginning of a highly personalized journey. It remains impossible right now to accurately answer the question, 'How long do I have?' Which of course is the question everyone wants answered.
Why your Gleason score matters
Prostate cancer severity is graded using a Gleason score, which ranges from 6 to 10. Lower scores (6–7) indicate slower-growing, less aggressive cancer cells, while higher scores (8–10) represent aggressive cancers more likely to spread quickly.
Biden's Gleason score of 9 signifies a highly aggressive prostate cancer that usually requires immediate and comprehensive treatment.
In my clinic, the moment of diagnosing advanced prostate cancer is always difficult, evoking fear, uncertainty and many questions. At that moment, I ask the patient to take a deep breath, slow down and work together as we build a care team.
This multidisciplinary team may include specialists from urology, medical oncology, radiation oncology, radiology and supportive care services. Each specialist contributes a unique perspective, helping to create a treatment plan that has the best interest of the patient and their life goals.
Prostate cancer treatment options
Localized prostate cancer can often be cured with treatments such as robotic-assisted prostate removal (prostatectomy) or radiation therapy. However, metastatic prostate cancer treatment shifts from cure to managing symptoms, controlling disease progression and maintaining quality of life. Common treatments for metastatic prostate cancer include:
Hormone therapy (androgen deprivation therapy, ADT): Blocks testosterone, essential for prostate cancer cell growth.
Chemotherapy: Drugs to slow cancer growth, particularly when hormone therapy alone is insufficient.
Radiation therapy: Targets metastatic lesions, reducing pain and symptoms, especially in bones.
Immunotherapy and precision medicine: Treatments leveraging the immune system to attack cancer cells or therapies targeting specific genetic markers.
Supportive care: Symptom relief and quality-of-life enhancement.
Advanced treatments effectively control metastatic prostate cancer but often come with side effects affecting daily life. Common side effects include fatigue, changes in sexual function, hot flashes, mood swings, and loss of muscle mass.
Treatment for metastatic prostate cancer depends on several factors: the patient's overall health, age, other medical conditions and personal preferences. President Biden's medical team will carefully personalize his treatment, aligning it closely with his unique health circumstances and quality-of-life goals.
How to take care of my prostate health?
A common question emerging from Biden's diagnosis is whether his cancer could have been detected sooner or if it impacted him during his presidency. The President of the United States gets excellent medical care, and the truth is that we may never know.
Instead of getting stuck on these unanswerable questions, I recommend we refocus on something we can control: our own health. Biden's diagnosis is a powerful reminder of our responsibility and opportunity to proactively manage our health.
As a urologist, I experience daily how unpredictable prostate cancer can be. Some patients show clear signs of the disease, while others surprise even me with aggressive or unexpected cases. Cancer doesn't discriminate, and its trajectory can be uncertain. But one factor we can all control is our approach to prevention and early detection.
Symptoms to watch for are blood in the urine or semen; needing to urinate more often, including waking up at night to urinate; and trouble getting started when urinating. Signs of more advanced disease can also include accidental leaking, pain in the back and bones, fatigue, weight loss and weakness.
Former President Biden's experience should be a call to action for us: Schedule regular health checkups, discuss prostate screening with your health-care provider, pay attention to your body's signals, and prioritize overall health.
By shifting the conversation from speculation about someone else's journey to actively engaging in your own, you're investing in the most priceless and valuable asset you have — your health.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Americans spend less time reading for fun and more time on screens, study finds
Americans spend less time reading for fun and more time on screens, study finds

Yahoo

time37 minutes ago

  • Yahoo

Americans spend less time reading for fun and more time on screens, study finds

Fewer Americans are opening a book for fun each day, with reading for pleasure in the United States down 40% over the past 20 years, a new study finds. Researchers from University College London and the University of Florida analyzed surveys from more than 230,000 Americans aged 15 and older between 2003 and 2023, tracking their daily reading habits. Results, published in the journal iScience on Wednesday, showed the share of people who picked up a book, magazine or e-reader every day dropped about 3% per year. Reading with children was also rare, the study found, with only 2% of adults reporting doing so on average every day. MORE: How phonics is making a comeback as millions of kids struggle to read However, those who did read spent more time doing so, averaging more than 90 minutes daily. "For me, one of the most important takeaways of this study is awareness of how little reading for children is happening," Jill Sonke, one of the study's lead authors as well as director of research initiatives and a research professor at the University of Florida Center for Arts in Medicine, told ABC News. "As a mother, reading to my children was a really important time for bonding as well as for relaxation and for stimulating my children's interest in reading and their imagination and creativity." The study also found that reading declined more sharply among Black Americans, those with less education or lower incomes, and people in rural areas, with gaps widening over the 20-year study period. The researchers speculated that the drop is likely tied to the rise of digital media, including social platforms, streaming and online browsing. "There's a correlation between time spent on digital media and reductions in reading time," Sonke said. "It does seem logical that the ways in which digital media compete for our time would be a factor in these declines in reading." The auhtors cautioned that less reading could affect health, well-being and literacy. Reading has been linked to stronger language skills, reasoning and empathy, they said. "I think it's important for people to understand that reading for pleasure is actually a health promoting activity," Sonke said. "We know that participating in the arts is a health behavior because it statistically results in improved health outcomes including well-being, social cohesion, mental health." MORE: Many students have still not regained pandemic-era losses in reading, math: Report The study authors say that national strategies often focus mainly on children. The authors suggested that adult reading habits also deserve attention, especially given their impact on health and well-being. The National Literacy Trust, an independent charity based in London that promotes literacy, advises setting aside 10 minutes before bed, carrying a book or e-reader during commutes and making reading a shared family activity. Even small changes can help bring reading back into daily life, the group notes. Raihan El-Naas, MD is a board-certified internal nedicine physician and current endocrinology fellow at Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center and a member of the ABC News Medical Unit. Solve the daily Crossword

Nym Rated a Top Performer by KLAS in First Report Dedicated to Autonomous Medical Coding
Nym Rated a Top Performer by KLAS in First Report Dedicated to Autonomous Medical Coding

Yahoo

time37 minutes ago

  • Yahoo

Nym Rated a Top Performer by KLAS in First Report Dedicated to Autonomous Medical Coding

Report underscores autonomous coding's rapid adoption and Nym's role in delivering efficiency and scalability to healthcare provider organizations NEW YORK, August 20, 2025--(BUSINESS WIRE)--Nym, a leader in autonomous medical coding, has been rated by KLAS Research as a top performer in the first report dedicated to the autonomous coding market: "Autonomous Coding 2025: A Promising Start for an Early Market." The August 2025 report formally recognizes autonomous coding as a distinct and growing segment within healthcare technology and highlights the vendors driving measurable value for providers. Key Takeaways Nym's Overall Performance Score: 89.6 (based on evaluations from 12 unique Nym customers) Customer feedback highlights: High satisfaction with implementation and ongoing support, including onboarding and training processes that ensure a smooth go-live and ease user adoption Read the full report. KLAS's findings show that autonomous medical coding is gaining momentum, with the most significant adoption today in radiology and emergency department settings, areas where providers are realizing substantial efficiency and accuracy gains. Customers across the market are eager to extend autonomous coding to additional specialties, underscoring its potential to address coding-related staffing shortages and operational bottlenecks. Nym's performance in the report reflects its ability to deliver the outcomes healthcare organizations are prioritizing as they scale autonomous coding. By fully automating coding with no human intervention, Nym eliminates overtime costs and contract labor needs while ensuring charts are coded in seconds, helping providers accelerate payment cycles and reduce administrative burden. Customers in the report consistently credited Nym's thoughtful onboarding and training for enabling a smooth go-live, rapid user adoption, and sustained productivity gains; capabilities essential for long-term success. The report's customer perspectives bring these outcomes to life. "Nym's [autonomous medical coding engine] has completely transformed our ability to get through the volume of accounts. And one of our hospitals has a department that is one of the busiest in the country. I cut my need for human coders in half with this solution. And it was not that we eliminated all the positions. We just got rid of the overtime so our people can breathe now. We don't need to use contractors anymore, and we don't have open positions anymore. The solution has literally transformed our department. I cannot say enough good things about Nym." - Director, Autonomous Coding 2025: A Promising Start for an Early Market, August 2025. "KLAS's first report focused solely on autonomous coding marks a meaningful step forward for the industry," said Or Peles, CEO of Nym. "Nym's recognition as a top performer speaks to the progress we're making with providers today and the potential to deliver even greater value as adoption expands." Nym currently partners with over 25 healthcare organizations nationwide, including leading health systems, hospitals, and provider groups. About NymNym is the leader in transforming clinical language into actionable information, removing inefficiencies that add billions to the cost of care. By combining industry-leading technology with clinical expertise and a deep understanding of medical language, Nym accurately decodes medical charts in a way that is fast, explainable, and compliant. The Company's innovative autonomous medical coding solution translates provider notes into accurate diagnostic and billing codes in seconds, with zero human intervention and over 95% accuracy. Nym's solution delivers audit-ready documentation for every code it generates, ensuring complete visibility into coding decisions. Based in New York City with R&D capabilities in Tel Aviv, Nym is backed by leading investors including PSG, Addition, GV, Bessemer Venture Partners, Dynamic Loop Capital, and Tiger Global. Learn more at KLAS is a research and insights firm on a mission to improve healthcare delivery by amplifying the provider's voice. Working with thousands of healthcare professionals and clinicians, KLAS gathers data on software, services, and medical equipment to deliver timely reports and statistical overviews. Learn more at View source version on Contacts Media Contact Nicole Parisernicole@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wisdom, the AI-Powered Dental Revenue Cycle Management Platform, Raises $28M to Accelerate Product Innovation and Capitalize on Rapid Growth
Wisdom, the AI-Powered Dental Revenue Cycle Management Platform, Raises $28M to Accelerate Product Innovation and Capitalize on Rapid Growth

Yahoo

time37 minutes ago

  • Yahoo

Wisdom, the AI-Powered Dental Revenue Cycle Management Platform, Raises $28M to Accelerate Product Innovation and Capitalize on Rapid Growth

SAN FRANCISCO, August 20, 2025--(BUSINESS WIRE)--AI in revenue cycle management has become top of mind across the healthcare industry, but when it comes to the dental market, dentists are lacking the modern tools used by their medical counterparts. That's the problem that AI-powered dental RCM platform, Wisdom, is on a mission to solve. The company announced today the successful completion of its $21M Series A capital raise led by Permanent Capital Ventures (PCV), a venture capital firm that partners with founders to build go-to-market engines for enterprise scale. Aquiline, a private investment firm specializing in financial services and technology, joined the round, alongside existing investor and Co-Founder, Juxtapose, a leading creation-oriented investment firm. Juxtapose followed their recent $7M Seed investment, reaffirming the firm's commitment to Wisdom's continued growth and innovation. This funding brings Wisdom's total capital raised to $28M since its founding in 2023. The overwhelming majority of independent practices and small dental groups in America struggle with the administrative burden of running a profitable business, leaving over $20 billion of earned revenue uncollected despite spending billions of dollars on salaries for in-house revenue management. Wisdom, which has already collected hundreds of millions of dollars for its clients and saved them up to 50% of collection costs, takes a highly differentiated approach to administrative workflows by bringing AI agents and human experts together to maximize revenue collections, predictability, transparency and patient satisfaction, thereby freeing dentists and their staff to focus on delivering outstanding patient care. Since its inception, Wisdom has rapidly expanded by combining advanced, proprietary AI-driven technology with US-based billing experts. This unique approach has propelled Wisdom to achieve exceptional client satisfaction, underscored by a consistently high Net Promoter Score of 73 and strong organic growth. Over 50% of Wisdom's signed deals still come through referrals. Wisdom was awarded Top Dental Billing Company by Healthcare Business Review earlier this year and was named a 2025 Dental Innovator Award winner by DentalIQ for its AI-assisted dental billing service. Wisdom is led by CEO Stoyan Kenderov, an accomplished technologist, product leader and executive with over 25 years of success building new products and transforming organizations into customer-obsessed teams that drive growth and profitability, most recently as COO of business payments platform Plastiq. Prior to his time at Plastiq, Stoyan held senior leadership roles at LendingClub, Intuit, Quicken, and many other international technology companies. Stoyan is joined by Wisdom Co-Founder and Chief Dental Billing Officer Ashley Bond, who previously founded and led the award-winning nationwide billing service, Bond Dental Billing. "We are thrilled to partner with PCV and Aquiline as we continue our mission to transform dental billing and revenue management," said Kenderov. "Their proactive approach and expertise in building scalable enterprises align perfectly with our vision to significantly enhance financial outcomes and operational efficiency for dental practices." PCV's investment in Wisdom reflects the firm's strategy of supporting innovative startups poised for transformational growth. "Wisdom has created an impressive track record by uniquely integrating AI technologies with deep industry expertise," said Mike Gamson, Co-Founder and Managing Partner at Permanent Capital Ventures. "We see immense potential in their ability to scale and redefine revenue management solutions in the dental sector and beyond." Aquiline has a history of building scaled revenue cycle management businesses, and this investment in Wisdom marks the firm's second investment supporting the dental industry. "While we continue to see significant innovation across dental, the market is filled with point solutions and generally lacks modern, end-to-end platforms, especially across the rev cycle process," said Dante La Ruffa, Partner at Aquiline. "We believe that Stoyan and his team are reimagining the future of dentistry, starting with the key pain points that have historically inhibited dentists from maximizing their time with patients." This funding will enable Wisdom to further enhance its technology platform, accelerate market expansion, and continue building out its exceptional team to better serve dental offices of all sizes - from private practices to multi-location dental groups across the country. "The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Stoyan and his team have moved quickly but thoughtfully to build a solution which really moves the needle for dentists while preserving the value of human expertise," said Andy Stein, Partner at Juxtapose. For more information about Wisdom and its innovative dental billing solutions, please visit About Juxtapose Juxtapose is a creation-oriented investment firm building and funding industry-defining technology companies. Juxtapose's concept development and investment process is focused on multi-decade opportunities in complex industries that leverage the team's expertise in software and technology, human-centered design, commercial strategy, executive talent assessment, and private capital markets. Juxtapose has built and led the financing of companies across software, healthcare, and tech-enabled services that have raised over $1B of external, follow-on private capital. Founded in 2016, Juxtapose now has over $1B AUM. About Permanent Capital Ventures Permanent Capital Ventures is an expansion stage venture capital firm that partners with extraordinary founders building AI application businesses. We lean in with unique go-to-market expertise in the moments after product-market fit has been established to help unlock the path to enterprise scale. About Aquiline Aquiline Capital Partners LP ("Aquiline") is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management across the firm's three strategies in private equity, venture, and credit. Additional information is available on the firm's website: Aquiline Capital Partners LP ("Aquiline") is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management and has deployed approximately $7.4 billion of capital across the firm's three strategies in private equity, venture, and credit. View source version on Contacts Aquiline media contact:Charlie Cumiskey, Apella Advisors+44 (0)7958 964446, aquiline@ Wisdom Media contact:Brian Becker, Wisdombrian@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store